Skip to main content

Table 1 Fatty acid analysis of RWPE-1 cells that were supplemented with various fatty acids at the end of 48 hours of supplementation of various fatty acids

From: Effect of n-3 and n-6 unsaturated fatty acids on prostate cancer (PC-3) and prostate epithelial (RWPE-1) cells in vitro

Fatty acids in RWPE-1

Composition percentage (%)

 

Linolelaidic acid

Linoleic acid

γ-linolenic acid

Arachidonic acid

α-linolenic acid

EPA

DHA

Control

2.15 ± 0.50

0.38 ± 0.09

0.76 ± 0.13

0.92 ± 0.14

0.47 ± 0.09

0.86 ± 0.13

2.58 ± 0.49

LA(50 μM)

0.12 ± 0.05***

1.59 ± 0.13**

0.49 ± 0.08*

1.76 ± 0.39**

0.19 ± 0.02*

1.73 ± 0.41*

2.60 ± 0.60

LA(150 μM)

0.18 ± 0.08***

0.52 ± 0.18*

2.62 ± 0.64**

0.70 ± 0.12

0.33 ± 0.09

0.78 ± 0.14

0.69 ± 0.06**

GLA(25 μM)

1.64 ± 0.03*

0.19 ± 0.03*

1.44 ± 0.09*

21.95 ± 2.99***

3.48 ± 0.57**

N.D

0.43 ± 0.14**

GLA(50 μM)

1.13 ± 0.02**

0.65 ± 0.06*

1.01 ± 0.13*

27.21 ± 0.02***

8.45 ± 0.19***

N.D

0.65 ± 0.01**

GLA(75 μM)

N.D

0.99 ± 0.17*

12.34 ± 0.55***

19.63 ± 1.47***

10.59 ± 1.42***

N.D

0.88 ± 0.07**

AA(50 μM)

19.58 ± 0.83***

7.3 ± 0.19**

4.57 ± 1.45**

7.01 ± 0.74**

0.69 ± 0.27*

5.52 ± 0.76***

6.63 ± 0.17**

AA(100 μM)

21.22 ± 0.29***

7.19 ± 0.18***

4.04 ± 1.10**

10.28 ± 0.43***

1.60 ± 0.22**

10.63 ± 1.27***

9.30 ± 1.68**

ALA(50 μM)

0.56 ± 0.08***

0.39 ± 0.07

0.97 ± 020

0.49 ± 0.05*

0.62 ± 0.13*

2.04 ± 0.41*

2.60 ± 0.64

ALA(150 μM)

0.17 ± 0.07***

0.53 ± 0.08

0.77 ± 0.23

0.85 ± 0.13

0.86 ± 0.10*

1.92 ± 0.60**

0.43 ± 0.05**

EPA(50 μM)

0.92 ± 0.02**

4.67 ± 0.59***

0.83 ± 0.02

N.D

2.61 ± 0.84**

1.14 ± 0.25

6.27 ± 0.34***

EPA(100 μM)

1.24 ± 0.32**

1.83 ± 0.34**

1.65 ± 0.34*

1.07 ± 0.04

0.53 ± 0.17

4.42 ± 0.43***

7.22 ± 0.44***

DHA(50 μM)

1.14 ± 0.41**

1.41 ± 0.07**

0.93 ± 0.32

2.94 ± 0.59**

N.D

N.D

14.95 ± 0.63***

DHA 100 μM

1.54 ± 0.09*

1.38 ± 0.32**

2.41 ± 0.64**

2.29 ± 0.00**

0.44 ± 0.06

N.D

15.35 ± 0.08***

  1. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control.